Predicting Response/Resistance to HER2-Targeted Therapies in the Neoadjuvant Setting

Chapter 10

William J. Gradishar, MD, and Joyce O’Shaughnessy, MD, discuss patient factors that predict the likelihood of response to HER2-targeted therapies in the neoadjuvant therapies.

Chapter 1

HER2+ Metastatic Breast Cancer: Insights from the Lab and Clinic

Joyce O’Shaughnessy, MD, and Hope S. Rugo, MD, discuss recent treatment advances for patients with HER2+ metastatic breast cancer.

Chapter 2

Trastuzumab Resistance in Metastatic Breast Cancer

Joyce O’Shaughnessy, MD, and Hope S. Rugo, MD, discuss strategies for overcoming trastuzumab resistance in patients with breast cancer.

Chapter 3

Advances in the Biologic Role of HER2 in Metastatic Breast Cancer

Hope S. Rugo, MD, Claudine Isaacs, MD, and William J. Gradishar, MD, discuss the most exciting advances in the biologic role of HER2 in metastatic breast cancer.

Chapter 4

Strategies in the Management of HER2+ Metastatic Breast Cancer

Hope S. Rugo, MD, and Joyce O’Shaughnessy, MD, review the current recommendations for the management of metastatic HER2 positive breast cancer.

Chapter 5

First-Line Treatment With a Lapatinib-Based Regimen

Hope S. Rugo, MD, and Joyce O’Shaughnessy, MD, discuss the use of lapatinib as a first-line treatment option.

Chapter 6

Strategies for Overcoming Trastuzumab Resistance

Hope S. Rugo, MD, and Joyce O’Shaughnessy, MD, discuss practical strategies for treating patients who experience resistance to trastuzumab treatment.

Chapter 7

New Anti-HER2 Agents or Targets for Metastatic Breast Cancer

Joyce O’Shaughnessy, MD, and William J. Gradishar, MD, review upcoming research regarding anti-HER2 agents for patients with metastatic breast cancer.

Chapter 8

HER2-Targeted Therapies in the Neoadjuvant Treatment Setting

William J. Gradishar, MD, discusses the current status of U.S. Food and Drug Administration approvals for HER2-targeted therapies for patients receiving neoadjuvant therapy.

Chapter 9

Lapatinib and the Neoadjuvant Treatment of HER2+ Breast Cancer

William J. Gradishar, MD, and Joyce O’Shaughnessy, MD, discuss the challenges related to the use of lapatinib in the neoadjuvant setting.

Chapter 11

AC-THP Versus TCHP Treatment

Joyce O’Shaughnessy, MD, Claudine Isaacs, MD, and Hope S. Rugo, MD, discuss the use of AC-THP compared with TCHP in women with breast cancer.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs